SCHEMBL25545930

SCHEMBL25545930

COc1ccc(-c2nc(Cl)sc2CCC(C)C)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PTGS2 P35354 3/20 0.40
PTGS1 P23219 2/20 0.40
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 3/20 0.38
CYP17A1 P05093 1/20 0.38
GRM2 Q14416 1/20 0.38
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
MAPT P10636 3/20 0.37
LMNA P02545 2/20 0.37
SLC10A2 Q12908 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25545935 0.91 PAX8 (0.38) ALDH1A1MEN1KMT2AGRM2MAPT
SCHEMBL25545925 0.88 ALDH1A1 (0.42) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL25545956 0.88 GRM2 (0.39) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL25545547 0.88 AAK1 (0.36) ALDH1A1SMN1; SMN2PTGS2PTGS1MAPK1
SCHEMBL25545938 0.86 DYRK1A (0.39) ALDH1A1MEN1KMT2AGRM2MAPT
SCHEMBL25546328 0.85 S1PR1 (0.43) ALDH1A1MEN1KMT2AKDM4EGRM2
SCHEMBL25546022 0.81 TRPV1 (0.35) ALDH1A1SMN1; SMN2KDM4EGRM2HTT
SCHEMBL25545544 0.79 S1PR4 (0.37) ALDH1A1SMN1; SMN2PTGS2PTGS1MAPT
SCHEMBL25545928 0.79 FBP1 (0.42) ALDH1A1MEN1KMT2APTGS2MAPK1
SCHEMBL25545941 0.77 LMNA (0.48) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885NPC1 2317/4885RAB9A 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.